Keytruda shows PFS benefit in first-line NSCLC study

Merck & Co. Inc. (NYSE:MRK) said PD-1 inhibitor Keytruda pembrolizumab met the primary endpoint in the Phase III KEYNOTE-024 trial

Read the full 202 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE